Table 1.
Baseline characteristics stratified using ejection fraction (EF) trajectory.
| EF Decrease 5+ % | No EF Change 5+ % | EF Increase 5+ % | p Value | |
|---|---|---|---|---|
| n | 33 | 84 | 62 | |
| Age | 78.00 [71.00, 80.00] | 77.00 [71.00, 81.00] | 72.00 [68.00, 80.00] | 0.136 |
| Male sex | 28 (84.8) | 77 (91.7) | 56 (90.3) | 0.54 |
| White race | 18 (54.5) | 49 (58.3) | 45 (72.6) | 0.122 |
| Hypertension | 27 (81.8) | 63 (75.0) | 47 (75.8) | 0.726 |
| Diabetes | 9 (27.3) | 21 (25.0) | 12 (19.4) | 0.619 |
| Coronary artery disease | 15 (46.9) | 35 (41.7) | 29 (46.8) | 0.789 |
| Coronary interventions | 8 (53.3) | 17 (48.5) | 14 (51.8) | 0.903 |
| Atrial fibrillation/flutter | 20 (60.6) | 46 (54.8) | 44 (71.0) | 0.138 |
| NYHA functional class | 0.344 | |||
| 1 | 0 (0.0) | 6 (8.3) | 3 (5.6) | |
| 2 | 11 (37.9) | 36 (50.0) | 28 (51.9) | |
| 3 | 16 (55.2) | 28 (38.9) | 19 (35.2) | |
| 4 | 2 (6.9) | 2 (2.8) | 4 (7.4) | |
| Body mass index (kg/m2) | 0.936 | |||
| >30 | 8 (24.2) | 22 (26.2) | 13 (21.0) | |
| 25–30 | 16 (48.5) | 36 (42.9) | 30 (48.4) | |
| <25 | 9 (27.3) | 26 (31.0) | 19 (30.6) | |
| eGFR (ml/min/1.73 m2) | 54.50 [40.59, 69.25] | 60.09 [48.12, 74.21] | 59.50 [47.25, 74.75] | 0.242 |
| Cardiac troponin T (ng/mL) | 0.07 [0.04, 0.11] | 0.04 [0.02, 0.10] | 0.04 [0.02, 0.09] | 0.141 |
| Baseline NT-proBNP (pg/mL) | 3063.00 [2287.00, 4250.00] | 2665.00 [1616.25, 5506.50] | 3068.50 [1763.75, 5172.00] | 0.745 |
| NT-proBNP change (pg/mL) | +2099.50 [142.50, 8772.25] | −85.00 [−699.75, 918.50] | +186.00 [−612.00, 2557.00] | 0.004 |
| ACE inhibitors | 12 (42.9) | 22 (32.4) | 14 (24.6) | 0.226 |
| ARB | 8 (28.6) | 12 (17.4) | 10 (17.9) | 0.417 |
| Beta Blocker | 19 (65.5) | 28 (40.6) | 23 (41.1) | 0.055 |
| NAC Staging (%) | 0.752 | |||
| 1 | 7 (38.9) | 18 (43.9) | 16 (43.2) | |
| 2 | 6 (33.3) | 17 (41.5) | 16 (43.2) | |
| 3 | 5 (27.8) | 6 (14.6) | 5 (13.5) |
Data are presented as median (interquartile range) or n (%). Abbreviations: eGFR, estimated glomerular filtration rate; NT-proBNP, aminoterminal pro-B-type natriuretic peptide; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NAC, National Amyloidosis Center.